Arvinas

Nurix Therapeutics

This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Dunad

This biopharmaceutical company develops orally bioavailable small-molecule protein degradation therapies for patients with oncology and central nervous system disorders.

Arrakis Therapeutics

This biopharmaceutical company develops oral, small-molecule medicines that target RNA to treat patients with cancer, cardiovascular conditions, neurodegeneration and rare genetic diseases.